Ziprasidone in treating bipolar child and adolescent patients: More research is warranted

Oral ziprasidone (ziprasidone hydrochloride) has been approved by the U.S. Food and Drug Administration (FDA) in 2001 for the treatment of schizophrenia, and acute manic or mixed episodes associated with bipolar disorder (BPD) with or without psychotic features. Ziprasidone intramuscular (ziprasidone mesylate) is FDA-approved for acute agitation in patients with schizophrenia.